Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 7, 2007; 13(5): 732-739
Published online Feb 7, 2007. doi: 10.3748/wjg.v13.i5.732
Published online Feb 7, 2007. doi: 10.3748/wjg.v13.i5.732
Table 3 Incidence of most frequent AEs, regardless of relationship to study drug (safety population)
| Adverse event | Tegaserod 6 mg b.i.d.(n = 303) (%) | Placebo(n = 303) (%) |
| Diarrhea | 11 (3.6) | 5 (1.7) |
| Abdominal pain | 5 (1.7) | 5 (1.7) |
| Nasopharyngitis | 1 (0.3) | 7 (2.3) |
| Transaminases increased | 3 (1.0) | 1 (0.3) |
| Nausea | 1 (0.3) | 3 (1.0) |
| Abdominal distension | 3 (1.0) | 0 |
| Dizziness | 2 (0.7) | 0 |
| Leukopenia | 1 (0.3) | 1 (0.3) |
| Urinary tract inflammation | 1 (0.3) | 1 (0.3) |
| Abdominal pain upper | 0 | 2 (0.7) |
- Citation: Lin SR, Ke MY, Luo JY, Yuan YZ, Wang JY, diTommaso S, Walter V, Huang J. A randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of tegaserod in patients from China with chronic constipation. World J Gastroenterol 2007; 13(5): 732-739
- URL: https://www.wjgnet.com/1007-9327/full/v13/i5/732.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i5.732